Table 1.
Characteristics of patients, n (%)
|
Baseline characteristic
|
n
= 48
|
| Age, median (range) | 70 (27-86) |
| Sex | |
| Males | 36 (75) |
| Females | 12 (25) |
| Histology | |
| Papillary | 24 (50) |
| Chromophobe | 9 (10.8) |
| Xp11 translocation | 1 (2.1) |
| Unclassified | 6 (12.5) |
| Mixed1 | 8 (16.7) |
| Grade (Fuhrman/ISUP) | |
| 1-2 | 6 (12.5) |
| 3 | 15 (31.3) |
| 4 | 4 (8.3) |
| NA | 23 (47.9) |
| Stage at diagnosis | |
| I-III | 33 (68.8) |
| IV | 15 (31.3) |
| Previous nephrectomy | |
| Yes | 41 (85.4) |
| No | 7 (14.6) |
| Metastasectomy | |
| Yes | 7 (14.6) |
| No | 41 (85.4) |
| ECOG PS | |
| 0 | 37 (77.1) |
| 1 | 11 (22.9) |
| IMDC score risk group | |
| Good | 19 (39.6) |
| Intermediate | 25 (52.1) |
| Poor | 2 (4.2) |
| NA | 2 (4.2) |
| Starting dose of pazopanib | |
| 800 mg | 31(64.6) |
| 600 mg | 10 (20.8) |
| 400 mg | 7 (14.6) |
1
Four tumors had mixed histology (clear-cell/papillary) with papillary histology prevalence and four tumors had mixed histology (clear-cell/chromophobe) with chromophobe histology prevalence.
NA: Not assessed/available; IMDC: International Metastatic Renal Cell Carcinoma Database Consortium; ECOG PS: Eastern Cooperative Oncology Group Performance Status; ISUP: International Society of Urological Pathology.